Short answer
Arcutis Biotherapeutics, Inc. (ARQT) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results released for quarter ended September 30, 2026.
Arcutis Biotherapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results released for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1
- Investor focus: commercial performance, cash position and updated outlook in the accompanying release
Item EX-99.1 · Exhibit EX-99.1
- Q3 product revenue $143.9M, up 45% YoY and 11% sequentially, confirming accelerating ZORYVE demand across formulations
- 2026 sales guidance raised to $535M-$545M from $525M-$540M, signaling stronger commercial visibility
- Q3 net income $8.8M versus $7.4M, with operating cash flow of $18.9M and liquidity of $259.8M
- SG&A rose to $99.6M from $62.4M, reflecting heavier marketing and expanded sales infrastructure that could pressure future margins
- Pipeline catalysts include FDA action date February 23, 2027 for infant atopic dermatitis and vitiligo Phase 2 results by year-end 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arcutis Biotherapeutics, Inc. 8-K filings
Get the next ARQT 8-K as it lands
Follow ARQT for push alerts, or ask the research agent what this filing means.